Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I bought 3,000 more. Thank you Adam.
People don't like the shorts but if you product is legit--buy mores shares and say thank you. Short's day will come and SOON.
“Discipline must come from trust and confidence.”
I just picked up 4,000 more shares. Time will tell if this works out for me--but I have a big smile on my face.
Janney
May 12, 2020
Marker Therapeutics, Inc.
MRKR - BUY
Price - $2.48 | Fair Value Estimate - $10.00
AML Phase II Initiation Timing Uncertain; Pancreatic Cancer Data At ASCO A Major Catalyst
The initiation of the Phase II study of MultiTAA T cell therapy in AML is on hold due to the COVID-19 pandemic affecting both Marker's clinical trial partners and study drug suppliers. Management has withdrawn the prior guidance on the timing of study initiation but we believe more clarity could be available in 2Q20. Updated clinical data from an investigator-sponsored Phase I/II study in metastatic pancreatic cancer will be presented at the upcoming ASCO annual meeting. Recall the interim data readout from the same study in July 2019 was associated with significant stock volatility so we believe the abstract to be released on this Wednesday and the actual presentation in June will be closely watched by investors. We continue to believe that clinical data to date support MultiTAA T cell therapy as a highly differentiated approach in treating both hematologic malignancies and solid tumors. Following an Orphan Drug designation for post-transplant AML, the initiation of the company-sponsored Phase II study will be a major milestone that we believe could happen in 2020. We reiterate our Buy rating and $10 fair value estimate on MRKR shares.
.
• Patient enrollment is paused at the moment. Recall the safety lead-in portion of the Phase II study in AML will enroll six patients, with three patients each in two groups. Marker had expected to receive all the final data and certificate of analysis (CoA) from the alternative supplier of the biologic agent by the end of 2Q20 and to submit to the FDA in 2H20. The partial clinical hold on the second group of patients will be lifted after the FDA has reviewed and accepted the above information. According to yesterday's quarterly updates, the alternative supplier had informed Marker that there would be a delay in providing the biologic agent. However, management confirmed that it is possible for patient enrollment in the first group, who will receive the biologic agent manufactured by the legacy supplier, and the second group happen simultaneously. Therefore, the real gating factor should be when the alternative supplier will be able to provide the required final data and CoA. According to management, the main objective of the safety lead-in phase is to identify any dose-limiting toxicity, which should be an easy hurdle to clear given the strong safety profile that the MultiTAA T cell therapy has demonstrated to date.
.
• Pancreatic cancer study update at ASCO will be a key event. Recall the interim data from the investigator-sponsored Phase I/II study was presented in July 2019 at an AACR conference. From nine evaluable patients who were responsive to chemotherapy, there was one case of complete response (CR), two partial responses (PRs), one mixed response (MR), and tumor volume shrinkage in six of eight evaluable patients. Both the clinical investigator of the study and a separate KOL that we talked to were excited about the outcome and see a pathway for MultiTAA T cell therapy to be incorporated into the treatment paradigm for metastatic pancreatic cancer. According to management, additional patients have received treatment and no cytokine release syndrome or neurotoxicity has been observed in the study. The study (NCT03192462) has a target enrollment of 45 patients and is actively recruiting patients. We expect the ASCO update to report data from a meaningful umber of new patients.
.
• Marker has a cash runway into 2Q21. Marker ended 1Q20 with cash and cash equivalents of approximately $40.3M and the company has entered into a Common Stock Purchase Agreement of up to $30 million with a long-term shareholder. Management expects the existing cash in combination with the access to additional capital to be sufficient to support the company's operations into 2Q 2021
.
https://urldefense.proofpoint.com/v2/url?u=https-3A__jms.bluematrix.com_sellside_EmailDocViewer-3Fencrypt-3D2be58d14-2D9488-2D4f1b-2D9ae1-2D1a59a3434bfe-26mime-3Dpdf-26co-3DJanney-26id-3DRWCrothers-40AmericanPortfolios.com-26source-3Dmail&d=DwMFaQ&c=OPFh8XEIaw6Qxrtar6A1iZCn6YtqNbwxi49dA1zsouM&r=8Jjh63VxmAYdpKc6VLg-yejEg_t79z6vJc6_tYOZ-o8&m=--WQB80tDOoRWxU6hO9DhL4dN_4n7AckuvEiufInSP4&s=oNAodTR4Km0YD5_4qnvvHjS6PzHLNxf9KG5Zol5ypII&e=
Copy and paste--you will not hear from me again.
Good luck
He sure did. But sure I like the tone here guys.
I will not post again.
Good luck and go MRKR.
We are all on the same team here guys. I was in on the last capital raise for tappimmune. Not trying to mislead anyone or play games.
How did you remember me--after all that time. Wow, you are incredible.
This information comes from a Research analyst at Janney
Marker continues to go back-and-forth with the FDA regarding questions about some “reagents” used in the production of Marker’s multiTAA therapies. Marker has already secured an alternate source and the issue now comes down to a matter of whether it will be faster to address the FDA’s questions or to secure an approval from the FDA to use this new supplier. As it stands, it appears the trial could be delayed for “several more months” at most, but there is the potential that the FDA could give them the go-ahead any day now.
There has been a lot of volume lately. I hope good things are coming.
Wow, to the few left on this board. Volume--for enum this huge.
Well there is a huge short position that is feeling the pinch. I only hope that pinch keeps getting tighter and tighter. :)
They are trying to clean up their balance sheet and get some working capital at the same time. I am giving them more money but I am sure that some that got into the deal with them will not.
After this is done it will put them in a better place when negotiating deals.
Side note--the short interest in the company has come down.
Volume today is 114,000 shares. The average volume is 33,000 shares.
That is a step in the right direction.
His vision for the company. Where we are and where he wants to go. He is a business guy, and I like his vision.
Talked with the new CEO and I am very impressed. Don't know what is going to happen but I do think we are in good hands.
My guess is that this stock is going to now start to move upward, slowly. Wall Street got their new CEO and two new board members. This is their first step to get this company headed in the right direction. I am sure much more will be coming--but a lot of times "the first step is the hardest."
I agree. Are physicians going jump on board or take a wait and see approach? You never know until you start seeing the numbers come in. My fingers are crossed and my toes too.
Is no one invested in FOLD but me? Where is everyone?
It is my understanding that the people that were in on capital raises were not happy with Tinkelenberg--for some of the reasons I had listed before (and some other reasons). The latest money would only be given with his resignation. I have no dog in this fight but at least some changes are being made and maybe this will lead to some support for the shareholders.
Well RK--that makes a lot sense of who is selling and why. I never thought of that. As you can tell, I am here for the long haul.
But on a personal note--you ROCK!!!!!!!!!
I know the OTC market is the wild west. Which is why I would like to see more steps to try and get this to a major market. It's been two years.The science may be good but the investor relations seems a little slim. Of course I am down $400,000 so am I allowed to whine a little bit? By the way, I may be down but I have not sold one share--so I have not lost a penny.
Who is selling their shares of Enum?
Who would be selling enum shares at 20 cents. It's not the insiders, and the capital raise I was in on cost me $1.00 a share--hard to believe any of them are taking an 80% lost. Over the last two years, there has been a lot of shares sold. I just wonder where they were coming from.
This site reminds me of Investor village, when I was in denderon. A good group of guys who know their stuff. Knowledge (and a little luck) is the key to investing. We used it and made a lot of money. I hope the same happens with this group and enum. I told some of the others that got in the Capital raise about this site--they may show up too.
I was in Denderon real early and out before the crash. Got lucky, real lucky. This is my biggest holding and it just hasn't panned out. Watching it drop from $1.00 to 21 cents has been painful. But I am patient. Ironically, I was was in the capital raise of PIRS. So I own them both. Small world.
Yes, I was in on that capital raise. 500,000 shares at $1.00 got 500,000 warrants at $2.00. At the time, I thought it was a great deal. So far, not so good. But the fat lady hasn't sung yet.
I have some of those warrants at $2.00, I have a long way to go to get in the money on those suckers.
Post-effective Amendment to Registration Statement
Does this mean they are going to raise a whole lot of money?
Where have you guys been all my life? I thought I knew about ENUM; but, I feel like I am in elementary school compared to you. I have had a big position and hoping for the best.